Affimed N.V Net debt/EBITDA
Quel est le Net debt/EBITDA de Affimed N.V?
Le Net debt/EBITDA de Affimed N.V. est 10.32
Quelle est la définition de Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA des entreprises dans Health Care secteur sur NASDAQ par rapport à Affimed N.V
Que fait Affimed N.V?
affimed (symbol: afmd) is a nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. natural killer cells, or nk-cells, and t-cells belong to the most potent cells of the human defense arsenal. affimed’s proprietary, next-generation bispecific antibodies, termed tandabs®, are designed to bring nk-cells or t-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. due to their novel tetravalent tandem architecture, which provides for four binding domains, the tandabs bind to specific targets on immune and cancer cells with high affinity. in addition, tandabs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. affimed beli
Entreprises avec net debt/ebitda similaire à Affimed N.V
- Magyar Bancorp a Net debt/EBITDA de 10.29
- Imperial Brands Plc a Net debt/EBITDA de 10.29
- China Oil And Gas a Net debt/EBITDA de 10.30
- Stanley Black & Decker a Net debt/EBITDA de 10.30
- The Clorox a Net debt/EBITDA de 10.32
- The Clorox a Net debt/EBITDA de 10.32
- Affimed N.V a Net debt/EBITDA de 10.32
- Lok'nStore Plc a Net debt/EBITDA de 10.32
- Independent Bank a Net debt/EBITDA de 10.33
- United Security Bancshares (CA) a Net debt/EBITDA de 10.34
- Weyerhaeuser Co a Net debt/EBITDA de 10.34
- Union Pacific a Net debt/EBITDA de 10.34
- Judges Scientific Plc a Net debt/EBITDA de 10.36